Novartis in-licenses Lubris Bio's lubricin for ophthalmic uses

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis (NVS +0.4%) exercises its option to in-license privately held Lubris BioPharma's ECF843, a recombinant human lubricin, for ophthalmic indications including dry eye.  The license is effective worldwide except Europe. Lubris retains the rights for non-ophthalmology uses. Financial terms are not disclosed.

Lubricin is a naturally occurring human protein that functions as a biological lubricant. A deficiency in this protein is common in dry eye sufferers.